Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (17)

2024

  1. Position of the Ibero-American Society of Neurourology and Urogynecology (SINUG) on the urodynamics (UDS) in women undergoing surgical treatment for stress urinary incontinence (SUI)

    Continence, Vol. 12

2022

  1. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 4

  2. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study

    Journal of Clinical Medicine, Vol. 11, Núm. 13

2021

  1. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Clinical benefit of tamsulosin and the hexanic extract of serenoa repens, in combination or as monotherapy, in patients with moderate/severe luts-bph: A subset analysis of the qualiprost study

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-14

2018

  1. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies

    BJU International, Vol. 122, Núm. 6, pp. 1049-1065

2011

  1. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder

    Value in Health, Vol. 14, Núm. 2, pp. 219-228

2010

  1. Overactive bladder: Is there a link to the metabolic syndrome in men?

    Neurourology and Urodynamics, Vol. 29, Núm. 8, pp. 1360-1364

2008

  1. A review of adherence to drug therapy in patients with overactive bladder

    BJU International, Vol. 102, Núm. 7, pp. 774-779

  2. Overactive Bladder and Continence Guidelines: Implementation, inaction or frustration?

    International Journal of Clinical Practice, Vol. 62, Núm. 10, pp. 1588-1593

2007

  1. Analysis of the value of the ICIQ-UI SF questionnaire and stress test in the differential diagnosis of the type of urinary incontinence

    Neurourology and Urodynamics, Vol. 26, Núm. 6, pp. 836-841

  2. Comparación entre el cuestionario "ICIQ-UI short form" y el "King's health questionnaire" como instrumentos de evaluación de la incontinencia urinaria en mujeres

    Actas Urologicas Espanolas, Vol. 31, Núm. 5, pp. 502-510

  3. Design and Validation of a New Screening Instrument for Lower Urinary Tract Dysfunction: The Bladder Control Self-Assessment Questionnaire (B-SAQ)

    European Urology, Vol. 52, Núm. 1, pp. 230-238

2006

  1. Overactive bladder: The importance of new guidance

    International Journal of Clinical Practice, Vol. 60, Núm. 10, pp. 1263-1271

2005

  1. Prevalencia de vejiga hiperactiva en España: Estudio poblacional

    Archivos Espanoles de Urologia, Vol. 58, Núm. 2, pp. 131-138

2000

  1. Validez del cuestionario king's health para la evaluación de la calidad de vida en pacientes con incontinencia urinaria

    Medicina Clinica, Vol. 114, Núm. 17, pp. 647-652

1999

  1. The development and preliminary validation of the IU-4 questionnaire for the clinical classification of urinary incontinence

    Actas urologicas españolas, Vol. 23, Núm. 7, pp. 565-572